Egfr-mutant non-small cell lung cancer accompanied by transient asymptomatic pulmonary opacities successfully treated with “stop-and-go” osimertinib

Keigo Kobayashi, Katsuhiko Naoki, Aoi Kuroda, Hiroyuki Yasuda, Ichiro Kawada, Kenzo Soejima, Tomoko Betsuyaku

Research output: Contribution to journalArticle


A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple che-motherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After 24 weeks, chest computed tomography (CT) revealed asymptomatic ground-glass opacities in both lobes. After four weeks of osimertinib discontinuation, imaging revealed rapid lung cancer progression. Osimertinib was resumed. After 11 weeks, CT revealed decreased lung nodules with no exacerbation of interstitial lung disease. We describe a patient who experienced transient asymptomatic pulmonary opacities during treatment with osimertinib, which was successfully managed by a “stop-and-go” approach.

Original languageEnglish
Pages (from-to)1007-1010
Number of pages4
JournalInternal Medicine
Issue number7
Publication statusPublished - 2018 Jan 1



  • Drug-induced pneumonitis
  • EGFR-T790M
  • Non-small cell lung cancer
  • Osimertinib
  • Stop-and-go
  • Transient asymptomatic pulmonary opacities

ASJC Scopus subject areas

  • Internal Medicine

Cite this